CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-12-10): AbbVie says most in hepatitis C study show improvement

Drug & Device Development

AbbVie says most in hepatitis C study show improvement

Last Updated: 2013-12-10 19:37:22 -0500 (Reuters Health)

(Reuters) - AbbVie Inc's all-oral hepatitis C therapy cured 96% of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, researchers said.

The study of 394 patients with the most common genotype 1 version of the virus tested the AbbVie regimen in people who had failed to be cured by the older standard treatments of pegylated interferon and ribavirin.

In results issued by AbbVie on Tuesday, nearly half of those in the Phase III trial dubbed Sapphire-II were prior null responders - a particularly difficult to treat group whose virus had no response to treatment with the older drugs.

The impressive cure rate after just 12 weeks of therapy mirrors the results seen last month in another late stage study that tested the all oral AbbVie regimen in potentially less challenging patients who had received no prior treatment for their hepatitis C.

Two percent of patients in the Sapphire-II trial experienced relapse or virologic breakthrough in which the virus rebounds after initially responding to treatment, while the discontinuation rate due to side effects was 1 percent.

Patients in whom there is no detectable levels of the virus in the blood 12 weeks after completing 12 weeks of therapy have achieved SVR, or sustained virologic response, which is considered cured.

Several companies are developing hepatitis C treatment regimens that do not require injectable interferon, which causes miserable flu like symptoms that lead many patients to discontinue or delay treatment.

Gilead Sciences is widely perceived by industry analysts to be the leader in the all-oral hepatitis C field that is expected to garner billions of dollars in annual sales. Gilead last week had one of its closely watched new drugs approved by the U.S. Food and Drug Administration.

AbbVie, Bristol-Myers Squibb Co and Merck & Co are all seen as potential rivals with oral regimens that have shown impressive cure rates and also cut the current treatment duration to 12 weeks or less from the current 24- or 48-week treatment regimens.

Some analysts have said AbbVie's ability to compete could be hampered by a larger number of pills that must be taken than some of the rival regimens.

The AbbVie regimen includes three experimental direct acting antiviral drugs that each attack a different target necessary for virus replication, plus the older drug ribavirin.

The drugs are the protease inhibitor ABT-450, whose effect is boosted by a widely used antiviral called ritonavir; the polymerase inhibitor ABT-333, and ABT-267 from a highly promising new class known as NS5A inhibitors.

The regimen currently involves four pills a day plus typically 2 ribavirin pills a day.

AbbVie, which has four more Phase III trials underway, is also testing its drugs without ribavirin - a medicine that can cause anemia and other side effects. But other companies are shooting for combination regimens that involve just one or two pills a day.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.